U.S. Patent Issued for Champions Biotechnology's Lead Oncology Drug
13 October 2009 - 11:52PM
PR Newswire (US)
BALTIMORE, Oct. 13 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a drug
development company with a preclinical platform able to predict
clinical effectiveness, accelerate development and enhance the
value of oncology drugs, today announced that the United States
Patent and Trademark Office issued a patent on September 29, 2009
for the company's tubulin inhibitors, including its lead compound
SG410. U.S. Patent No. 7,595,326 entitled "Synthesis of Novel
Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur
Analogs" protects the Company's composition of matter,
pharmaceutical composition, and method of treatment for SG410. The
patent is owned by Champions Biotechnology. "This patent solidifies
Champions' intellectual property position on SG410. We believe that
SG410, in the new Neowater formulation we developed, has the
potential to significantly impact the treatment of cancer," said
Doug Burkett, Ph.D., President of Champions Biotechnology, Inc.
"SG410 is Champions' first internal compound and is currently
undergoing Biomerk Tumorgraft(TM) evaluation. The results of SG410
tests in our predictive platform are expected to be available soon.
We are also actively evaluating high potential compounds to build
our oncology drug pipeline and expect to in-license additional
drugs in the near future. Studies suggest that evaluations of
compounds through Biomerk Tumorgrafts will lead to more successful
and efficient clinical development." For more information regarding
Champions Biotechnology's growing business and recent news, please
visit http://www.championsbiotechnology.com/. About SG410 SG410 is
an antimitotic inhibitor that was shown in Tumorgraft models to
target microtubule associated protein tau (MAPT) deficient tumors
with promising results as compared to a currently marketed and
leading chemotherapeutic drug. These antimitotic inhibitors target
MAPT (Microtubule-Associated Protein Tau) deficient tumors. In both
in vitro and in vivo models, SG410 has demonstrated promising
activity against prostate and pancreatic cancer. About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and tumor specific
data to enhance and accelerate the value of oncology drugs. The
Company's Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts, these Tumorgrafts closely
reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the
Company plans to sell, partner or license them to pharmaceutical
and/or biotechnology companies, as appropriate. The Company also
offers its predictive preclinical platform and tumor specific data
to physicians for personalized patient care and to companies for
evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
This press release contains "forward-looking statements" (within
the meaning of the Private Securities Litigation Act of 1995) that
inherently involve risk and uncertainties. Champions Biotechnology
generally uses words such as "believe," "may," "could," "will,"
"intend," "expect," "anticipate," "plan," and similar expressions
to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-K for the fiscal year ended April
30, 2009 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected
in the forward-looking statements are reasonable, they relate only
to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity,
performance or achievements may not meet these expectations. The
Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions
Biotechnology's expectations, except as required by law. For more
news and information on Champions Biotechnology, Inc., please visit
http://www.irgnews.com/coi/CSBR where you can find the CEO's video,
a fact sheet on the company, investor presentations, and more.
CONTACT: The Investor Relations Group, Inc. James Carbonara
+1-212-825-3210 DATASOURCE: Champions Biotechnology, Inc. CONTACT:
The Investor Relations Group, Inc., James Carbonara,
+1-212-825-3210 Web Site: http://www.championsbiotechnology.com/
Copyright